Use of a combination of apraclonidine and timolol to control intraocular pressure

• US 5,502,052 A
• Filed: 12/22/1994
• Issued: 03/26/1996
• Est. Priority Date: 04/26/1988
• Status: Expired due to Fees

• Current Assignee: Alcon Laboratories Incorporated (Alcon Incorporated)
• Original Assignee: Alcon Laboratories Incorporated (Alcon Incorporated)
• Inventors: DeSantis, Louis M.
• Primary Examiner(s): Fay, Zohreh
• Application Number:
  US08/364,831
• Time in Patent Office: 460 Days
• Field of Search: 514/236.2, 514/392, 514/913
• US Class Current: 514/236.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/13 Amines A61K31/04 takes precedence
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/42 Oxazoles
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 31/655 Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and other ophthalmic conditions are described. A method of controlling elevated intraocular pressure with those compositions is also described. The compositions contain a combination of an alpha-2 agonist (e.g., para-amino clonidine) and a beta blocker (e.g., betaxolol).

Claims

1. A method of controlling intraocular pressure which comprises applying topically to the affected eye a therapeutically effective amount of a composition comprising:

0.02 to 2.0 wt. % of para-amino clonidine or a pharmaceutically acceptable salt thereof, 0.01 to 3.0 wt. % of timolol or a pharmaceutically acceptable sale thereof, and a pharmaceutically acceptable vehicle therefor.